David Hong, MD
UT MD Anderson · Spero Therapeutics · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Hong, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07843550 · A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor MonotherapyM.D. Anderson Cancer Center · not yet recruiting · Solid Tumor · principal investigator
- Ph3NCT06059846 · A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Spero Therapeutics · completed · Urinary Tract Infection, Acute Pyelonephritis · study director
- Ph1/Ph2NCT05703854 · Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and OsteosarcomaM.D. Anderson Cancer Center · suspended · Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma · principal investigator
- Ph1NCT04044859 · ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)USWM CT, LLC · active not recruiting · Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) · principal investigator
- Ph1NCT03132922 · MAGE-A4ᶜ¹º³²T for Multi-TumorUSWM CT, LLC · active not recruiting · Urinary Bladder Cancer, Melanoma, Head and Neck Cancer · principal investigator
- Ph1NCT03098160 · Immunotherapy Study of Evofosfamide in Combination With IpilimumabThreshold Pharmaceuticals · unknown · Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck · principal investigator
- Ph1NCT02989064 · MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersAdaptimmune · completed · Urothelial Carcinoma, Head and Neck Cancer, Melanoma · principal investigator
- Ph1/Ph2NCT02499328 · Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckAstraZeneca · completed · Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · principal investigator
- Ph1NCT02118987 · Study of Omalizumab as Adjuvant Therapy in Chemotherapy DesensitizationDana-Farber Cancer Institute · completed · Drug Allergy · principal investigator
- Ph1NCT00903708 · LY2275796 in Advanced CancerM.D. Anderson Cancer Center · completed · Advanced Cancers · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.